Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Urinary excretions of free cortisol and corticosteroid sulfates were determined in 31 female controls, 77 breast cancer patients, 14 cases of colonic cancer, and 7 patients with bronchial carcinoma. Elevated corticosteroid sulfate excretion was present in 38% of patients with locally recurrent breast cancer and 30% of those with distant metastases, but in only 13% of the "early" breast cancer cases. A similar abnormality was seen in colonic cancer. Urinary free cortisol was usually normal. ACTH stimulation in a normal subject produced marked increases of both urinary free cortisol and corticosteroid sulfates. It is concluded that elevated corticosteroid sulfate excretion in cancer patients arises from an increased cortisol production rate combined with increased sulfurylation of the steroid. In bronchial carcinoma patients, changes similar to those occurring in the ACTH-treated normal subject may have resulted from ectopic ACTH production in the tumor.
 ...
PMID:The urinary excretion of corticosteroid sulfates by cancer patients. 17 59

The tumors from approximately 50% of patients with breast cancer contained estrogen receptor (ER). ER appeared more often and at higher levels in the tumors of postmenopausal women. Eleven out of 12 patients who had multiple ER assays from various metastatic sites showed no significant discrepancies in ER values. ER level appears to decrease as the duration of metastatic cancer increase. Patients with ER in the tumor more frequently have bone metastases than those without ER. Visceral metastases occurred more often with ER negative patients and appeared to have a more malignant course with significant shorter survival.
 ...
PMID:Estrogen receptor and natural course of breast cancer. 17

Human breast cancer was studied by in vitro techniques on tissue slices and extracts for a specific binding of estradiol and dihydrotestosterone. Estradiol receptors were found in 50 percent of patients in the premenopausal group and in 47 percent of patients in the postmenopausal group. The incidence of receptors in patients with metastatic disease was 32.5 percent. In 18 of 35 patients who were positive for receptor sites a remission was observed after a variety of endocrine treatment regimens. In contrast only 3 patients out of 43 with a negative binding pattern responded to treatment with nafoxidine for a very short time. The best correlation was found in the ovariectomized group. Between the responders and the nonresonders there is no difference in the quantitative receptor content. The same is valid in view of the duration of the remission.
 ...
PMID:Steroid hormone receptors in human breast cancer and clinical correlations. 17 16

The urinary excretion of corticosteroid sulfates and free cortisol were determined in 150 breast cancer patients. Four of 60 cases of early breast cancer (7%) and 26 of 90 patients with advanced breast cancer (29%) showed an elevated urinary corticosteroid sulfate excretion. Urinary free cortisol was usually normal. Estrogen receptor assays were performed on tumor samples from 67 breast cancer patients; 24 were from primary lesions obtained at mastectomy, 3 from inoperable primaries in patients with systemic metastases, and 40 from metastases. Sixteen of the primary breast cancers (67%), 26 of the metastases (65%) and 1 of the 3 inoperable primaries contained estrogen receptors. With 2 exceptions, patients with an increased urinary corticosteroid sulfate excretion also had estrogen receptor-containing tumors.
 ...
PMID:Corticosteroid sulfate excretion and estrogen receptors in breast cancer. 17 41

In vivo and in vitro studies bearing on tumor-specific and viral-associated antigenicity of human breast carcinomas were reviewed with particular attention to the following clinical considerations: (a) breast carcinomas arise in a nonrandom fashion; (b) in situ carcinomas precede invasive breast carcinomas; (c) invasive breast carcinomas behave in a heterogeneous fashion. Microscopically demonstrable lymphoreticuloendothelial responses, skin window tests, and leukocyte migration tests all indicate that tumor-specific antigenicity develops in assoication with the early phases of mammary carcinogenesis. Such antigenicity is maximally expressed in in situ carcinomas without associated invasive breast cancer and minimally in invasive breast cancers with metastases. Immunogenic breast cancer tissues commonly contain a protein component the antigenic and physicochemical properties of which are similar to those of a protein component of murine mammary tumor virus. Advances in our understanding and control of human mammary carcinogenesis and biological behavior are dependent on the clinicopathological characterization of individual patients and their breast tissues as well as on the analytical procedures used.
 ...
PMID:Biological considerations of tumor-specific and virus-associated antigens of human breast cancers. 17 36

Six patients with metastatic carcinoma of the breast underwent mediastinoscopy to obtain tissue for estrogen receptor analysis and pathologic confirmation of metastatic tumor. The indication for mediastioxcopy was an abnormal mediastinal accumulation of gallium in five patients, only two of whom had an abnormality noted on tomography. All six patients had tumor recovered by mediastinoscopy as demonstrated by pathologic examination and/or estrogen receptor assay, Therefore, the diagnosis of mediastinal metastases in breast cancer may be suggested by either chest roentgenograms, mediastinal tomography, or gallium scintigraphy. Mediastinoscopy is a safe, effective procedure capable of establishing the diagnosis of metastatic carcinoma of the breast and of procuring sufficient tissue for estrogen receptor analysis in patients without more readily accessible sites of metastases.
 ...
PMID:Mediastinoscopy: a diagnostic aid in metastatic carcinoma of the breast. 17 83

Since metastasizing breast cancer is hormone-related, hormonal therapy is based on control of tumor growth by elimination of the hormonal influence, hormone ablatives, or administration of steroid hormones to change the hormonal milieu of thehost organism. The time span during which hormonal therapy may be effective is extremely limited; therefore, this is not recommended for patients with an interval of less than 2 years between primary treatment and 1st manifestation of metastasis, patients with visceral metastasis, or women less than 5 years in the postmenopause. According to cooperative European and American studies remission rates for different types of endocrine therapy include: ovariectomy, 25-40%; adrenalectomy, 30-40%; hypophysectomy, 30-40%; androgen, 20%; and estrogens, 20-35%. Studies are underway concerning the use of antiestrogens (Nafoxidine and Tamoxifen) andinhibition of prolactin secretion. Investigations have shown that patients with proven estrogen receptors in the tumor tissue are particularly responsive to hormonal therapy. For patients with no determinable estrogen receptors, however, chemotherapy is perferable. Ovariectomy is recommended as the 1st measure for women in the premenopause, hormone additives for women longer than 5 years in the postmenopause, and for women in the 1st years after menopause ovariectomy in combination with a form of polychemotherapy. For patients with short free intervals polychemotherapy with another endocrine measure, for pleuracarcinosis and liver metastosis high corticosteroid dosages, and for metastases in the central nervous system radiatio treatment with high corticosteroid dosages are recommended.
 ...
PMID:[Hormone therapy of breast cancer]. 18 Mar 75

The first 18 months' experience of the Breast Diagnostic Center of Jefferson Medical College have been reviewed. Almost 14,000 patients were screened for breast disease, using a combination of clinical examination. Xeroradiography, and thermography. In this group of 14,000 women, 106 cases of cancer were discovered, in incidence of almost 8 per 1000 women screened. Of these 106 cases of cancer, 45.3% were clinically occult or not recognized by clinical examination, and within this group at the time of mastectomy only a small percent had any evidence of axillary lymph node metastases. The combination of several technics of examination is proving to be more reliable for the early detection of breast cancer than any of the technics alone, and programs such as these may make a significant difference in the death rate from breast cancer.
 ...
PMID:Mass screening for breast disease. Results, problems, and expectations. 18 1

Assays of estrophile protein (ER) in 161 patients with no previous additive or ablative hormonal therapy have been analyzed; 47.2 percent were ER positive; 52.8 percent ER negative. A total of 37.5 percent of premenopausal and 50.8 percent of postmenopausal patients had ER-positive tumors. The effects of additive and ablaive hormonal therapy were observed in 75 patients; 63.5 percent of the ER-positive group and 8.6 percent of the ER-negative group responded, but the incidence in the ER-negative group is thought to be spuriously high. The level of the ER content in the ER-positive group did not influence the degree of response. The ER-negative group had a shorter life span after discovery of the tumor and was more likely to develop dominant visceral metastases. Of 15 patients followed with sequential ER assays after hormonal therapy (additive and/or ablative), 14 demonstrated substantial falls in ER levels but these did not correlate with the clinical response. Tumor assayed in nine patients after irradiation of the lesion contained no demonstrable ER. ER assays of breast cancer tissue proved to be a useful but imperfect tool in predicting clinical progress following hormonal maneuvers but some readings may be spuriously low due to imperfect techniques of measurement, prior exogenous hormonal administration or hormonal ablation, and previous irradiation of the tumor.
 ...
PMID:The surgical implications of estrophile protein estimations in carcinoma of the breast. 18 56

The effect on prognosis of the presence of ovarian metastases was studied in patients oophorectomized in treatment of progressive breast cancer. At laparotomy, 28% (n = 42) were found to have ovarian metastases. This high percentage indicates that cases studied were in a relatively progressed state. In the cases with ovarian metastases, the clinical course of the disease was no different to those histologically free from metastases. It appears therefore that the presence of secondary ovarian metastases at oophorectomy is of no therapeutic or prognostic significance. The time interval between oophorectomy and mastectomy, however, apparently does have a bearing on the progress of the disease.
 ...
PMID:[Ovarian metastases in breast carcinoma]. 19 99


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>